Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKCA Akcea Therapeutics	$18.17	$18.16	$8.00 ▼ $21.70	$1.85B	1.45	361,806 shs	N/A
BPMC Blueprint Medicines	$127.90 -0.2%	$93.96	$73.04 ▼ $128.36	$8.26B	0.83	1.10 million shs	4.44 million shs
ELAN Elanco Animal Health	$13.44 0.0%	$10.77	$8.02 ▼ $18.80	$6.67B	1.49	5.12 million shs	3.13 million shs
JAZZ Jazz Pharmaceuticals	$108.80 -0.6%	$108.68	$95.49 ▼ $148.06	$6.71B	0.38	837,841 shs	637,537 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKCA Akcea Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
BPMC Blueprint Medicines	+0.39%	+34.42%	+25.80%	+44.68%	+25.72%
ELAN Elanco Animal Health	0.00%	+0.52%	+39.73%	+24.35%	-26.04%
JAZZ Jazz Pharmaceuticals	-0.79%	+2.28%	-7.39%	-19.79%	+4.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKCA Akcea Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	0.9139 of 5 stars	2.2	1.0	0.0	0.0	2.4	0.8	0.6
ELAN Elanco Animal Health	2.0718 of 5 stars	2.2	1.0	0.0	0.3	2.5	3.3	0.0
JAZZ Jazz Pharmaceuticals	4.9056 of 5 stars	4.5	1.0	0.0	4.0	2.5	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKCA Akcea Therapeutics	0.00	N/A	N/A	N/A
BPMC Blueprint Medicines	2.33	Hold	$129.71	1.41% Upside
ELAN Elanco Animal Health	2.43	Hold	$15.17	12.89% Upside
JAZZ Jazz Pharmaceuticals	2.92	Moderate Buy	$184.00	69.12% Upside

Current Analyst Ratings Breakdown

Latest AKCA, JAZZ, ELAN, and BPMC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
6/3/2025	BPMC Blueprint Medicines	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$150.00 ➝ $135.00
6/3/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$202.00
6/2/2025	BPMC Blueprint Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$130.00 ➝ $129.00

(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKCA Akcea Therapeutics	$488.54M	3.78	$0.51 per share	35.54	$5.78 per share	3.14
BPMC Blueprint Medicines	$562.12M	14.69	N/A	N/A	$4.67 per share	27.39
ELAN Elanco Animal Health	$4.43B	1.51	$2.78 per share	4.84	$12.63 per share	1.06
JAZZ Jazz Pharmaceuticals	$4.06B	1.65	$22.16 per share	4.91	$59.36 per share	1.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKCA Akcea Therapeutics	$40.77M	$0.48	N/A	N/A	N/A	-12.34%	-8.94%	-8.02%	N/A
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	196.77	N/A	-13.19%	-77.49%	-20.84%	7/30/2025 (Estimated)
ELAN Elanco Animal Health	-$1.23B	$0.74	33.59	15.10	2.50	4.60%	6.78%	3.03%	8/14/2025 (Estimated)
JAZZ Jazz Pharmaceuticals	$414.83M	$7.50	15.32	5.82	1.04	11.60%	29.30%	9.72%	7/30/2025 (Estimated)

Latest AKCA, JAZZ, ELAN, and BPMC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	ELAN Elanco Animal Health	$0.31	$0.37	+$0.06	$0.14	$1.17 billion	$1.19 billion
5/6/2025	Q1 2025	JAZZ Jazz Pharmaceuticals	$4.65	$1.68	-$2.97	-$1.52	$984.16 million	$897.84 million
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKCA Akcea Therapeutics	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKCA Akcea Therapeutics	N/A	12.17	11.78
BPMC Blueprint Medicines	1.15	2.85	2.80
ELAN Elanco Animal Health	0.66	2.55	1.31
JAZZ Jazz Pharmaceuticals	1.46	4.26	3.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKCA Akcea Therapeutics	19.27%
BPMC Blueprint Medicines	N/A
ELAN Elanco Animal Health	97.48%
JAZZ Jazz Pharmaceuticals	89.14%

Insider Ownership

Company	Insider Ownership
AKCA Akcea Therapeutics	1.50%
BPMC Blueprint Medicines	4.21%
ELAN Elanco Animal Health	0.89%
JAZZ Jazz Pharmaceuticals	4.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKCA Akcea Therapeutics	248	101.60 million	N/A	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.22 million	Optionable
ELAN Elanco Animal Health	9,800	496.65 million	491.54 million	Optionable
JAZZ Jazz Pharmaceuticals	3,200	61.65 million	57.92 million	Optionable

AKCA, JAZZ, ELAN, and BPMC Headlines

Recent News About These Companies

Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report?

June 5 at 12:36 PM | zacks.com

Bruce C. Cozadd Sells 500 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock

June 5 at 8:24 AM | insidertrades.com

Lmcg Investments LLC Increases Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

June 5 at 7:14 AM | marketbeat.com

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives $182.79 Consensus PT from Brokerages

June 5 at 3:06 AM | americanbankingnews.com

Wellington Management Group LLP Sells 3,026 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

June 4 at 4:23 AM | marketbeat.com

Roche/Jazz share positive phase 3 results for lung cancer combination therapy

June 3 at 10:17 PM | pmlive.com

Roche and Jazz Link Drug Combo to Improved Survival in Phase III Lung Cancer Trial

June 3 at 10:17 PM | biospace.com

Jazz Pharmaceuticals' (JAZZ) Buy Rating Reaffirmed at Needham & Company LLC

June 3 at 8:11 AM | marketbeat.com

Jazz Pharmaceuticals plc (JAZZ)’s Zepzelca Combo Boosts Survival in ES-SCLC

June 3 at 2:16 AM | insidermonkey.com

2 Healthcare Stocks to Keep an Eye On and 1 to Turn Down

June 2 at 7:21 PM | msn.com

Jazz Pharmaceuticals succeeds in late-stage study of lung cancer treatment

June 2 at 7:21 PM | msn.com

Jazz Pharmaceuticals Announces ZepzelcaÂ® (lurbinectedin) and Atezolizumab (TecentriqÂ®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

June 2 at 4:16 PM | prnewswire.com

Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025

June 2 at 12:35 PM | prnewswire.com

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

June 2 at 1:49 AM | marketbeat.com

Jazz Is in the “Goldilocks Zone” With New Cancer Data at ASCO25

May 31, 2025 | biospace.com

What is Zacks Research's Forecast for JAZZ Q2 Earnings?

May 31, 2025 | marketbeat.com

MassMutual Private Wealth & Trust FSB Increases Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

May 31, 2025 | marketbeat.com

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Acquired by Mackenzie Financial Corp

May 31, 2025 | marketbeat.com

Q2 Earnings Estimate for JAZZ Issued By Zacks Research

May 31, 2025 | americanbankingnews.com

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Centre Asset Management LLC

May 30, 2025 | marketbeat.com

Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025

May 29, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
3 Undervalued Stocks Wall Street Is Getting Wrong
By Gabriel Osorio-Mazilli | May 12, 2025
View 3 Undervalued Stocks Wall Street Is Getting Wrong
3 Companies to Buy on This Early Cycle Recovery
By Gabriel Osorio-Mazilli | June 3, 2025
View 3 Companies to Buy on This Early Cycle Recovery
Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming?
By Jeffrey Neal Johnson | May 8, 2025
View Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming?

AKCA, JAZZ, ELAN, and BPMC Company Descriptions

Akcea Therapeutics NASDAQ:AKCA

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.

Blueprint Medicines NASDAQ:BPMC

$127.90 -0.20 (-0.16%)

Closing price 04:00 PM Eastern

Extended Trading

$128.35 +0.45 (+0.36%)

As of 04:39 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Elanco Animal Health NYSE:ELAN

$13.44 -0.01 (-0.04%)

Closing price 03:59 PM Eastern

Extended Trading

$13.42 -0.01 (-0.07%)

As of 04:20 PM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Jazz Pharmaceuticals NASDAQ:JAZZ

$108.80 -0.65 (-0.59%)

Closing price 04:00 PM Eastern

Extended Trading

$108.61 -0.19 (-0.17%)

As of 05:09 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time